ProRelix Research, a leading CRO and one of the foremost regulatory consulting firm, delivers end-to-end Global Regulatory Affairs Services that ensure strategic compliance and global market access. Our specialized regulatory consulting for clinical trials facilitates sponsors with precision-driven guidance and regulatory excellence.
ProRelix Research provides complete support in regulatory consultation and services for clinical trials, helping sponsors and research teams navigate complex global regulatory requirements with confidence. We specialize in preparing and managing all types of Regulatory Submissions and Applications, including Clinical Trial Applications (CTA), Investigational New Drug (IND) submissions, Marketing Authorization Applications (MAA), New Drug Applications (NDA), Biologics License Applications (BLA), and Abbreviated New Drug Applications (ANDA). Our services also cover medical device registration and local representation for regulatory approvals, ensuring effective coordination with regulatory authorities worldwide. With our expert guidance and strategic approach, ProRelix Research ensures every submission meets international standards, enabling faster approvals and smoother market access.
Contact us at the Regulatory Consulting nearest to you or submit a business inquiry online.
ProRelix Research offers complete support in preparing, compiling, and submitting the necessary documentation for regulatory filings, ensuring that all forms and submissions are accurate, timely, and meet the expectations of regulatory bodies.
ProRelix Research assists sponsors in preparing and submitting Clinical Trial Applications (CTAs) to regulatory authorities with precision and compliance. Our regulatory experts ensure that every submission aligns with country-specific guidelines, ethical standards, and ICH-GCP requirements, enabling smooth approval for study initiation across multiple geographies.
Our team supports sponsors throughout the IND preparation and submission process, including compiling preclinical, clinical, and CMC data. ProRelix Research ensures that all documentation meets FDA and global regulatory expectations, facilitating faster approvals to begin first-in-human studies with minimized delays.
ProRelix Research provides complete MAA management services for obtaining product marketing authorization in the EU and other regions. From dossier preparation in CTD/eCTD format to regulatory liaison and post-submission support, we help pharmaceutical companies navigate complex EMA procedures seamlessly.
Our experts guide sponsors through the NDA submission process, ensuring that every module, from clinical study reports to risk management plans, is accurate, compliant, and ready for FDA evaluation. ProRelix Research focuses on reducing review timelines and achieving faster product commercialization.
ProRelix Research specializes in BLA submissions by ensuring comprehensive documentation of biologic product manufacturing, quality, and safety. Our regulatory professionals coordinate closely with clients to ensure CMC and clinical sections meet FDA’s rigorous standards, facilitating successful biologics approval.
We support generic drug developers with complete ANDA preparation and submission, ensuring bioequivalence data, stability reports, and manufacturing details are well-documented. ProRelix Research helps clients navigate FDA guidance efficiently, reducing approval time for generic market entry.
ProRelix Research provides end-to-end regulatory support for medical device registration across the US, EU, and emerging markets. Our services include technical file preparation, conformity assessments, and coordination with notified bodies to ensure timely and compliant product approvals.
We act as your authorized local representative in multiple regions to communicate with regulatory authorities, manage submissions, and handle post-approval compliance. ProRelix Research ensures continuous regulatory support, helping global clients maintain seamless communication and compliance with local laws.
Offering strategic advice on regulatory pathways, submission strategies, and regulatory compliance.
Assisting with the preparation and submission of regulatory documents, including CTAs, INDs, NDAs, and more.
Navigating the approval process with ethics comittees and institutional review boards (IRBs)
Guiding clients through market access strategies, including pricing, reimbursement, and health economics.
Conducting audits to ensure that trials are in full regulatory compliance.
Securing approval for a clinical trial requires close collaboration with various regulatory authorities and ethics committees. ProRelix Research fosters strong, professional relationships with these bodies to ensure efficient communication and approval processes.
Our team liaises with regulatory authorities to expedite the review and approval process, facilitating interactions that lead to faster decision-making. Moreover, we engage with institutional review boards (IRBs) and ethics committees to ensure that all studies adhere to the highest ethical standards.
By securing ethical clearance and regulatory approval, ProRelix Research minimizes potential risks and ensures that trials are conducted with the utmost respect for patient safety and well-being.
ProRelix Research is a leading pharmaceutical, medical device, and FDA regulatory consulting firm providing complete CRO services solutions for global clients. We offer expert pharmaceutical regulatory consulting services to help companies meet complex international requirements and achieve faster, compliant product approvals. Our team also provides specialized medical device regulatory consulting, guiding manufacturers through documentation, registration, and market access processes. As one of the most trusted FDA regulatory consulting firms, ProRelix Research delivers strategic guidance, submission management, and continuous regulatory support, ensuring efficiency, quality, and successful product launches worldwide.
The foundation of a successful clinical trial lies in a well-crafted regulatory strategy. ProRelix Research works closely with sponsors to develop tailored regulatory plans that align with the therapeutic objectives and desired outcomes of each study. By analyzing the specific requirements of regulatory authorities in different regions, we can offer strategic guidance on critical decisions, such as selecting the right countries for conducting trials, optimizing regulatory submissions, and determining appropriate regulatory pathways.
Our team helps sponsors build clear and actionable roadmaps to navigate complex regulatory environments, ensuring compliance with evolving standards and addressing any challenges that may arise. We identify potential regulatory roadblocks early in the process, reducing delays and accelerating time-to-market for new therapies.
Regulatory affairs services help pharmaceutical and medical device companies comply with national and international regulations to gain product approval. These services include documentation, submission management, and communication with health authorities such as the FDA, EMA, and CDSCO.
Regulatory affairs consulting ensures that all clinical trial activities meet global regulatory standards. At ProRelix Research, our experts assist with Clinical Trial Applications (CTA), Investigational New Drug (IND) submissions, and ongoing compliance to ensure trials start on time and run smoothly.
Global regulatory submissions support covers dossier preparation, data review, eCTD publishing, and communication with multiple regulatory agencies. ProRelix Research provides end-to-end assistance across the US, EU, and Asia to streamline global product approvals.
Filing an NDA involves compiling clinical, preclinical, and manufacturing data into a CTD/eCTD format and submitting it to regulatory agencies for marketing approval. Our team ensures all NDA modules are compliant, accurate, and ready for timely submission.
ProRelix Research manages the entire MAA process, from dossier preparation to regulatory correspondence. Our expertise in EU procedures and local regulatory frameworks ensures smooth submission and faster marketing approval for new products.
These services help manufacturers register, certify, and maintain compliance for medical devices across global markets. ProRelix Research handles technical documentation, CE marking, and local representation to ensure your devices meet country-specific standards.
An IND (Investigational New Drug) application is submitted to the FDA for approval to start clinical trials in the US, while a CTA (Clinical Trial Application) is filed with regulatory bodies in other countries like the EU or India. ProRelix Research prepares both, ensuring all regulatory and ethical requirements are met.
A BLA (Biologics License Application) is required for biologic products, whereas an ANDA (Abbreviated New Drug Application) is for generic drug approvals. ProRelix Research helps sponsors compile and submit these applications efficiently, ensuring compliance with FDA standards.
Local representation ensures smooth communication with regional regulatory authorities and faster responses to queries. ProRelix Research acts as your authorized representative in key markets, managing submissions and maintaining ongoing compliance.
Global quality and regulatory services help maintain consistency, compliance, and efficiency across multiple regions. At ProRelix Research, we combine quality assurance with regulatory expertise to accelerate global drug development and approval timelines.
Bringing new therapies requires accuracy, efficiency, and regulatory care. We offer clinical trial solutions that reduce risk, shorten timelines, and ensure compliance, turning ideas into successful outcomes.
Be the first to know the latest trends in clinical research, real-world case studies, and industry secrets.
ProRelix Research is the rapidly growing Contract/ Clinical Research Organization (CRO) with multi-country service capability supporting phase 1, 2, 3, & 4 clinical trials of Pharma, Biotech, Biopharma, Medical Device, Nutraceutical & Herbal companies to conduct in the USA, India, Europe & South East Asia.